CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

Detailed price information for Amicus Therapeutics (FOLD-Q) from The Globe and Mail including charting and trades.

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications

On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) ...